Variability of Fluconazole Concentration in Critically Ill Patients
NCT ID: NCT02491151
Last Updated: 2017-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2014-10-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Therapeutic Drug Monitoring of Fluconazole in Critically Ill Patients
NCT04252027
Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients
NCT02666716
Optimal Dosage of Caspofungin in Critically Ill Patients
NCT01994096
Pharmacokinetics of Micafungin in Critically Ill Patients
NCT01716988
Therapeutic Drug Monitoring of Antifungals in Intensive Care Units
NCT04502771
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with fluconazole.
* Written informed consent obtained from patient.
* Written informed consent obtained from representative of patient.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jan-Willem C Alffenaar
Associate Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan-WIllem Alffenaar, PharmD PhD
Role: PRINCIPAL_INVESTIGATOR
University Medical Center Groningen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Groningen
Groningen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Boonstra JM, Martson AG, Sandaradura I, Kosterink JGW, van der Werf TS, Marriott DJE, Zijlstra JG, Touw DJ, Alffenaar JWC. Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01554-20. doi: 10.1128/AAC.01554-20. Print 2021 Feb 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FLU-14O28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.